Data gathered: April 15
AI Stock Analysis - Incyte (INCY)
Analysis generated June 17, 2024. Powered by Chat GPT.
Incyte Corporation (INCY) is a well-established biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The firm's portfolio includes products aimed at treating various cancer types, inflammatory diseases, and more. Incyte leverages its strong research and development capabilities to maintain a competitive edge in an evolving market.
Stock Alerts - Incyte (INCY)
 |
Incyte | April 10 Price is down by -5.5% in the last 24h. |
|
Incyte | April 9 Price is down by -5.9% in the last 24h. |
|
Incyte | April 8 Price is down by -5.5% in the last 24h. |
|
Incyte | March 29 Job postings are down by 17.7% in the last couple of days. |
Alternative Data for Incyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 128 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 68,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 36 | Sign up | Sign up | Sign up |
| Patents | 516 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 939 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,799 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,374 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,445 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 257 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 62 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,040 | Sign up | Sign up | Sign up |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
| Price | $59.22 |
| Target Price | Sign up |
| Volume | 2,040,000 |
| Market Cap | $11B |
| Year Range | $55.17 - $83.38 |
| Dividend Yield | 0% |
| PE Ratio | 379.13 |
| Analyst Rating | 36% buy |
| Earnings Date | April 29 '25 |
| Industry | Biotechnology |
In the news
 |
Incyte to Report First Quarter Financial ResultsApril 9 - Yahoo |
 |
Incyte price target lowered by $8 at UBS, here's whyApril 9 - Thefly.com |
|
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7 - Yahoo |
 |
Franklin Resources Inc. Acquires 143,059 Shares of Incyte Co. (NASDAQ:INCY)April 7 - ETF Daily News |
|
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)April 6 - Yahoo |
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gainsApril 2 - MarketWatch |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.14B | 86M | 1.05B | 106M | 180M | 1.070 |
| Q2 '24 | 1.04B | 93M | 951M | -445M | -367M | -1.820 |
| Q1 '24 | 880M | 61M | 820M | 170M | 114M | 0.640 |
| Q4 '23 | 1.01B | 70M | 943M | 201M | 294M | 1.060 |
| Q3 '23 | 918M | 60M | 858M | 171M | 261M | 1.100 |
Insider Transactions View All
| Flannelly Barry P filed to sell 52,714 shares at $67.9. March 18 '25 |
| Flannelly Barry P filed to sell 52,913 shares at $67.9. March 18 '25 |
| Flannelly Barry P filed to sell 33,567 shares at $67.7. March 18 '25 |
| Denton Sheila A. filed to sell 25,848 shares at $70. March 6 '25 |
| Denton Sheila A. filed to sell 25,848 shares at $74.1. February 28 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Oct 8, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Incyte (INCY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Incyte?
The Market Cap of Incyte is $11B.
What is Incyte's PE Ratio?
As of today, Incyte's PE (Price to Earnings) ratio is 379.13.
When does Incyte report earnings?
Incyte will report its next earnings on April 29 '25.
What is the current stock price of Incyte?
Currently, the price of one share of Incyte stock is $59.22.
How can I analyze the INCY stock price chart for investment decisions?
The INCY stock price chart above provides a comprehensive visual representation of Incyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Incyte shares. Our platform offers an up-to-date INCY stock price chart, along with technical data analysis and alternative data insights.
Does INCY offer dividends to its shareholders?
As of our latest update, Incyte (INCY) does not offer dividends to its shareholders. Investors interested in Incyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Incyte?
Some of the similar stocks of Incyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.